Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer

NCT00748163 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.

NCT NCT00748163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00748163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer
Lead sponsor
Masonic Cancer Center, University of Minnesota
Phase
Phase 2
Overall status
Withdrawn
Start date
August 31, 2008
Completion date
August 31, 2008
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer